摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1221496-24-7

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1221496-24-7
化学式
C36H38O5
mdl
——
分子量
550.695
InChiKey
WPMBXXTUZXGKHN-FOJCDXFYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    711.7±60.0 °C(predicted)
  • 密度:
    1.22±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

反应信息

  • 作为反应物:
    描述:
    戴斯-马丁氧化剂 作用下, 以 二氯甲烷 为溶剂, 生成
    参考文献:
    名称:
    C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization
    摘要:
    Modifications to the sugar portion of C-aryl glycoside sodium glucose transporter 2 (SGLT2) inhibitors were explored, including systematic deletion and modification of each of the glycoside hydroxyl groups. Based on results showing activity to be quite tolerant of structural change at the C-5 position, a series of novel C-5 spiro analogues was prepared. Some of these analogues exhibit low nanomolar potency versus SGLT2 and promote urinary glucose excretion (UGE) in rats. However, due to sub-optimal pharmacokinetic parameters (in particular half-life), predicted human doses did not meet criteria for further advancement. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.01.075
  • 作为产物:
    描述:
    溴甲苯二正丁基氧化锡4-甲氧基溴苄四丁基碘化铵 作用下, 以 甲苯 为溶剂, 反应 4.0h, 生成
    参考文献:
    名称:
    C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization
    摘要:
    Modifications to the sugar portion of C-aryl glycoside sodium glucose transporter 2 (SGLT2) inhibitors were explored, including systematic deletion and modification of each of the glycoside hydroxyl groups. Based on results showing activity to be quite tolerant of structural change at the C-5 position, a series of novel C-5 spiro analogues was prepared. Some of these analogues exhibit low nanomolar potency versus SGLT2 and promote urinary glucose excretion (UGE) in rats. However, due to sub-optimal pharmacokinetic parameters (in particular half-life), predicted human doses did not meet criteria for further advancement. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.01.075
点击查看最新优质反应信息